US4525359A
(en)
*
|
1982-12-10 |
1985-06-25 |
Greenway Frank L Iii |
Treatment for selective weight control
|
US5069911A
(en)
*
|
1985-02-05 |
1991-12-03 |
Sandoz Ltd. |
Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
|
US6004972A
(en)
*
|
1988-05-10 |
1999-12-21 |
The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College |
Therapeutic process for the treatment of the pathologies of type II diabetes
|
US5700800A
(en)
*
|
1988-05-10 |
1997-12-23 |
Ergo Science Incorporated |
Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
|
US5585347A
(en)
*
|
1988-05-10 |
1996-12-17 |
Ergo Science Incorporated |
Methods for the determination and adjustment of prolactin daily rhythms
|
US5468755A
(en)
*
|
1988-05-10 |
1995-11-21 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Therapeutic process for the treatment of the pathologies of Type II diabetes
|
US5830895A
(en)
*
|
1988-05-10 |
1998-11-03 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Methods for the determination and adjustment of prolactin daily rhythms
|
US5668155A
(en)
*
|
1988-05-10 |
1997-09-16 |
The General Hospital Corporation |
Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
|
US5344832A
(en)
*
|
1990-01-10 |
1994-09-06 |
The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College |
Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
|
US5744477A
(en)
*
|
1988-05-10 |
1998-04-28 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Method for treatment of obesity using prolactin modulators and diet
|
US5006526A
(en)
*
|
1988-10-17 |
1991-04-09 |
Louisiana State University |
Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
|
CA2030174C
(en)
*
|
1990-01-10 |
1996-12-24 |
Anthony H. Cincotta |
Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
|
IL112106A0
(en)
*
|
1993-12-22 |
1995-03-15 |
Ergo Science Inc |
Accelerated release composition containing bromocriptine
|
US20010016582A1
(en)
|
1997-04-28 |
2001-08-23 |
Anthony H. Cincotta |
Method and composition for the treatment of lipid and glucose metabolism disorders
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
CA2434033A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
PL205343B1
(pl)
*
|
2001-01-26 |
2010-04-30 |
Schering Corp |
Zastosowanie inhibitora wchłaniania sterolu
|
PT1353694E
(pt)
*
|
2001-01-26 |
2008-03-12 |
Schering Corp |
Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
|
SI1353696T1
(sl)
*
|
2001-01-26 |
2007-04-30 |
Schering Corp |
Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
|
AR032643A1
(es)
*
|
2001-01-26 |
2003-11-19 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
|
CA2447884A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
US7354923B2
(en)
*
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
US7718802B2
(en)
|
2001-08-10 |
2010-05-18 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
US7456184B2
(en)
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
US7655658B2
(en)
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
US7732451B2
(en)
|
2001-08-10 |
2010-06-08 |
Palatin Technologies, Inc. |
Naphthalene-containing melanocortin receptor-specific small molecule
|
AU2002331064B2
(en)
|
2001-08-10 |
2007-08-23 |
Palatin Technologies, Inc. |
Peptidomimetics of biologically active metallopeptides
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
DK1429756T3
(da)
*
|
2001-09-21 |
2007-03-19 |
Schering Corp |
Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
|
PT1427409E
(pt)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
|
CA2504916A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
ES2318274T3
(es)
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
EP1601668B1
(en)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US7192944B2
(en)
*
|
2003-03-07 |
2007-03-20 |
Schering Corp. |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7727990B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine and keto-piperazine compounds
|
US7968548B2
(en)
|
2003-05-01 |
2011-06-28 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine compounds with diamine groups
|
US7727991B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific single acyl piperazine compounds
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7709484B1
(en)
|
2004-04-19 |
2010-05-04 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
US7834017B2
(en)
|
2006-08-11 |
2010-11-16 |
Palatin Technologies, Inc. |
Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
|
EP2727587A1
(en)
*
|
2012-10-30 |
2014-05-07 |
Pharnext |
Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
|